Table 1.
All patients (n=1263) |
Surgery alone (n=574) |
Surgery + PORT (n=689) |
p-value | |
---|---|---|---|---|
Median age at diagnosis | 54 | 59 | 51 | <0.0001 |
[years] | (10 to 88) | (10 to 88) | (15 to 82) | |
Range | ||||
Gender | <0.0001 | |||
Male | 634 (50.2%) | 253 (39.9%) | 381 (60.1%) | |
Female | 629 (49.8%) | 321 (51.0%) | 308 (49.0%) | |
Paraneoplastic Syndrome | ||||
Myasthenia gravis | 464 (37.2%) | 159 (34.3%) | 305 (65.7%) | <0.0001 |
None | 745 (59.7%) | 389 (52.2%) | 356 (47.8%) | |
Other | 38 (3.1%) | 15 (39.5%) | 23 (60.5%) | |
Pathological Stage | ||||
II | 870 (68.9%) | 449 (51.6%) | 421 (48.3%) | <0.0001 |
III | 393 (31.1%) | 125 (31.8%) | 268 (68.1%) | |
Median tumor size [cm] | 5.8 | 5.5 | 6 | 0.046 |
Range | (0.7 to 22) | (1 to 20.5) | (0.7 to 22) | |
Histology | ||||
A/AB | 360 (30.3%) | 225 (62.5%) | 135 (37.5%) | <0.0001 |
B1/B2/B3 | 827 (69.7%) | 321 (38.8%) | 506 (61.2%) | |
Chemotherapy | 180 (14.9%) | 58 (32.2%) | 122 (67.8%) | 0.0003 |